切换导航
  • 比较产品
我的购物车

EasySep™ Release人Biotin正选试剂盒

采用可解离磁珠技术对生物素偶联抗体标记的人的细胞进行免疫磁珠正选
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17653_C

免选磁珠正选出不含磁珠的生物素化抗体标记人细胞

产品优势

  • 只需不到40分钟，从人组织中分离出用生物素化抗体标记的高纯度细胞
  • 无需洗涤去除EasySep™ Releasable RapidSpheres™可解离磁珠

产品组分包括

  • EasySep™ Release人Biotin正选试剂盒（产品号 #17653）
    • EasySep™Biotin正选抗体混合物，0.5 mL
    • EasySep™ Releasable RapidSpheres™ 50201磁珠，1 mL
    • EasySep™Release缓冲液（浓缩），3 x 1 mL
    • 抗人CD32阻断剂，1 mL
main product photo
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
    string(7) "18000_C" NULL
    2. string(7) "20144_C" NULL
总览
实验数据
产品说明书及文档
相关材料与文献
相关产品

总览

使用 EasySep™ Release人Biotin正选试剂盒，可通过免疫磁性正选，轻松从新鲜或冻存的人外周血单个核细胞（PBMCs）及经洗涤的白细胞单采样本中分离出高纯度、且不含磁珠的生物素化抗体标记人细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性，已在发表的研究中广泛应用超过20年。

该EasySep™阳性分选流程中，首先用能识别生物素和磁珠（称为EasySep™可解离磁珠）的抗体复合物标记目标细胞。与传统磁珠结合目标细胞不同，这些磁珠具有可解离的特性。经EasySep™磁极分选后，使用解离试剂可将结合的磁珠从EasySep™分选的生物素抗体标记细胞上移除，非目标细胞则被定向去除。最终分选获得的细胞组分含有高纯度生物素阳性细胞，可立即用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。使用该EasySep™试剂盒分选之后，细胞表面仍结合有抗体复合物，并可能与Brilliant Violet™偶联的抗体、聚乙二醇修饰的蛋白质或其他化学相关配体相互作用。

本产品替代了EasySep™人生物素正选试剂（产品号#18553），可提供高纯度无磁珠标记的细胞。

了解更多关于免疫磁珠EasySep™技术的工作原理。探索更多为您的实验流程优化的产品，包括培养基、添加剂、抗体等配套试剂。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyPlate™ Magnet (Catalog #18102) • EasyEights™ Magnet (Catalog #18103)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞，树突状细胞（DCs），粒细胞及其亚群，造血干/祖细胞，巨噬细胞，骨髓基质细胞，间充质干/祖细胞，单核细胞，单个核细胞，髓系细胞，NK 细胞，其它细胞系，血浆，T 细胞
 
种属
人
 
样本来源
Leukapheresis，其它细胞系，PBMC
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep
 
研究领域
免疫
 

查看更多 显示更少

Data Figures

Typical EasySep™ Release Human Biotin Positive Selection Profile with PBMCs

Figure 1. Typical EasySep™ Release Human Biotin Positive Selection Profile with PBMCs

Starting with fresh PBMCs, the purities of the start and final isolated fractions are 34.6% and 97.1%, respectively, using a biotinylated anti-human CD45RO antibody and EasySep™ Release Human Biotin Positive Selection Kit (as assessed by labeling with CD45RO and CD45RA).

Typical EasySep™ Release Human Biotin Positive Selection Profile with Mouse Splenocytes

Figure 2. Typical EasySep™ Release Human Biotin Positive Selection Profile with Mouse Splenocytes

Starting with mouse splenocytes, the purities of the start and final isolated fractions are 58.4% and 95.1%, respectively, using a biotinylated anti-mouse CD19 antibody and EasySep™ Release Mouse Biotin Positive Selection Kit (as assessed by labeling with CD19 and CD45R/B220).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet 1
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
1000157901 or lower
Language
English
Document Type
Product Information Sheet 2
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
1000157902 or higher
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Product Name
EasySep™ Release Human Biotin Positive Selection Kit
Catalog #
17653
Lot #
All
Language
English

Resources and Publications

Educational Materials (8)

EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Brochure
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
Positive Selection of PE- or Biotin-Conjugated Antibody Labeled Cells with Releasable Rapidspheres™
Scientific Poster
Positive Selection of PE- or Biotin-Conjugated Antibody Labeled Cells with Releasable Rapidspheres�...

Publications (1)

Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. N. G. Im et al. Cancer immunology research 2022 sep

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell-leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity. See related Spotlight by Zhao and Melenhorst, p. 1040.
View publication
View All Publications

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyPlate™ Magnet (Catalog #18102) • EasyEights™ Magnet (Catalog #18103)
Sample Source Leukapheresis, Other, PBMC
Selection Method Positive
标记抗体
  1. 山羊抗小鼠 IgG (H+L) 抗体，多克隆
    山羊抗小鼠 IgG (H+L) 抗体，多克隆

    抗小鼠IgG（H+L）山羊多克隆抗体

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。